One year on from the first approved TIL Therapy in the US, and with Canada and EMA expected to make approval decisions in the coming months, this is a pivotal time for drug developers looking to address treatment-resistant solid tumors.

Returning for its 7th year, the TIL Therapies Summit remains the go-to forum for this close-knit community, created with the mission to transform end-to-end TIL development and deliver best-in-class therapies to treat solid tumor indications with significant unmet needs.

With more patients being treated than ever, join this global collective of biopharma, academic thought leaders, clinicians, and patients as they share their cutting-edge research into engineered TIL, easier manufacturing, and lived experiences with TIL Therapies.